四川弘合生物科技

Honghe Biotech is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and psychiatric disorders. The company's lead program, HH-018, is a first-in-class GPR139 agonist currently in Phase 1 clinical trials for the treatment of schizophrenia. Additionally, Honghe Biotech is advancing a pipeline of candidates targeting GPR119 and GLP-1 receptors to address unmet needs in type 2 diabetes and obesity. By leveraging its expertise in G protein-coupled receptor (GPCR) drug discovery, the company aims to provide novel treatment options for patients with complex chronic conditions.